Sporadic inclusion-body myositis and its similarities to Alzheimer disease brain. Recent approaches to diagnosis and pathogenesis, and relation to aging.

Sporadic inclusion-body myositis (s-IBM) is the most common, debilitating and progressive muscle disease beginning at the age 50 or later. The most characteristic pathologic feature is vacuolar degeneration of muscle fibers accompanied by intrafiber congophilia and clusters ("tangles") of paired-helical filaments, containing phosphorylated tau. An unusual feature of sporadic inclusion-body myositis is accumulation within its abnormal muscle fibers of several proteins that are characteristic of Alzheimer disease brain, including epitopes of beta-amyloid precursor protein (betaAPP), phosphorylated tau, alpha-1-antichymotrypsin, apolipoprotein E, and presenilin-1. Indicators of oxidative stress are also present within abnormal s-IBM muscle fibers. In this review, we describe new advances seeking the pathogenic mechanism of sporadic inclusion-body myositis. We hypothesize on the possible pathogenic role of abnormally accumulated proteins, and we propose that important contributory factors leading to inclusion-body myositis are the milieu of muscle-fiber aging and oxidative stress. In addition, we present evidence that overexpression of adenovirus-transferred betaAPP gene in cultured human muscle fibers induces aspects of the inclusion-body myositis phenotype, and suggest that betaAPP-overexpression is an early event in the pathogenic cascade causing inclusion-body myositis.

[1]  W. Engel,et al.  Fourteen Newly Recognized Proteins at the Human Neuromuscular Junctions‐and Their Nonjunctional Accumulation in Inclusion‐Body Myositisa a , 1998, Annals of the New York Academy of Sciences.

[2]  W. Engel,et al.  Light and electron microscopic immunolocalization of presenilin 1 in abnormal muscle fibers of patients with sporadic inclusion-body myositis and autosomal-recessive inclusion-body myopathy. , 1998, The American journal of pathology.

[3]  G. Drewes,et al.  Tau domains, phosphorylation, and interactions with microtubules , 1995, Neurobiology of Aging.

[4]  W. Engel,et al.  Rapid examination of muscle tissue , 1963, Neurology.

[5]  W. Engel,et al.  Increase of nitric oxide synthases and nitrotyrosine in inclusion‐body myositis , 1996, Neuroreport.

[6]  U. Andersson,et al.  Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. , 1997, Arthritis and rheumatism.

[7]  A. Levey,et al.  Presenilin‐1 protein expression in familial and sporadic Alzheimer's disease , 1997, Annals of neurology.

[8]  A. Engel,et al.  Immunocytochemical study of CD45 T cell isoforms in inflammatory myopathies. , 1995, The American journal of pathology.

[9]  S. Prusiner,et al.  Human prion diseases , 1994, Annals of neurology.

[10]  W. Engel,et al.  Abnormal accumulation of prion protein mRNA in muscle fibers of patients with sporadic inclusion-body myositis and hereditary inclusion-body myopathy. , 1994, The American journal of pathology.

[11]  W. Engel,et al.  β‐Amyloid precursor epitopes in muscle fibers of inclusion body myositis , 1993 .

[12]  J S Beckman,et al.  Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. , 1996, The American journal of physiology.

[13]  K S Kosik,et al.  The Molecular and Cellular Biology of Tau , 1993, Brain pathology.

[14]  J. Buxbaum,et al.  Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. , 1997, The New England journal of medicine.

[15]  W. Engel,et al.  βAPP gene transfer into cultured human muscle induces inclusion‐body myositis aspects , 1997 .

[16]  K. Grzeschik,et al.  The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor , 1987, Nature.

[17]  W. Engel,et al.  Apolipoprotein E immunoreactive deposits in inclusion-body muscle diseases , 1994, The Lancet.

[18]  J. Bilbao,et al.  Ubiquitin expression in inclusion body myositis. An immunohistochemical study. , 1993, Archives of Pathology & Laboratory Medicine.

[19]  E. Otomo,et al.  Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease , 1991, Brain Research.

[20]  W. Engel,et al.  Prion protein is abnormally accumulated in inclusion‐body myositis , 1993, Neuroreport.

[21]  J. A. Alexander,et al.  Hepatitis C and inclusion body myositis. , 1996, The American journal of gastroenterology.

[22]  H. Goebel,et al.  Expression of cell adhesion molecules in inflammatory myopathies , 1995, Journal of Neuroimmunology.

[23]  H. Goebel,et al.  Cytokine Expression Profile in Idiopathic Inflammatory Myopathies , 1996, Journal of neuropathology and experimental neurology.

[24]  A. D. Roses,et al.  Association of apolipoprotein E allele €4 with late-onset familial and sporadic Alzheimer’s disease , 2006 .

[25]  S. Jentsch.  Ubiquitin-dependent protein degradation: a cellular perspective. , 1992, Trends in cell biology.

[26]  W. Engel,et al.  New advances in the understanding of sporadic inclusion‐body myositis and hereditary inclusion‐body myopathies , 1995, Current opinion in rheumatology.

[27]  W. Engel,et al.  Sporadic inclusion-body myositis and hereditary inclusion-body myopathies: diseases of oxidative stress and aging? , 1998, Archives of neurology.

[28]  M. Andary,et al.  Inclusion body myositis and transitional cell carcinoma of the bladder: significant resolution of symptoms after tumor excision. , 1997, Archives of physical medicine and rehabilitation.

[29]  L. Forno,et al.  Antibodies to presenilin proteins detect neurofibrillary tangles in Alzheimer's disease. , 1996, The American journal of pathology.

[30]  W. Engel,et al.  Difference in Expression of Phosphorylated Tau Epitopes between Sporadic Inclusion‐body Myositis and Hereditary Inclusion‐body Myopathies , 1996, Journal of neuropathology and experimental neurology.

[31]  P. Cohen,et al.  Molecular dissection of the paired helical filament , 1995, Neurobiology of Aging.

[32]  F. Morrell,et al.  Dilantin in the Treatment of Trigeminal Neuralgia , 1958, Neurology.

[33]  W. Engel,et al.  Immunocytochemical localization of ubiquitin in inclusion body myositis allows its light‐microscopic distinction from polymyositis , 1992, Neurology.

[34]  Shin J. Oh,et al.  Rimmed vacuoles of inclusion body myositis and oculopharyngeal muscular dystrophy contain amyloid precursor protein and lysosomal markers , 1993, Brain Research.

[35]  K. Weisgraber,et al.  Apolipoprotein E and apolipoprotein E messenger RNA in muscle of inclusion body myositis and myopathies , 1996, Annals of neurology.

[36]  B. Sommer,et al.  Neuronal Localization of Presenilin-1 and Association with Amyloid Plaques and Neurofibrillary Tangles in Alzheimer’s Disease , 1997, The Journal of Neuroscience.

[37]  J. Marx.  Boring in on beta-amyloid's role in Alzheimer's. , 1992, Science.

[38]  W. Engel,et al.  Immunolocalization of transcription factor NF-κB in inclusion-body myositis muscle and at normal human neuromuscular junctions , 1998, Neuroscience Letters.

[39]  E. Mandelkow,et al.  Tau as a marker for Alzheimer's disease. , 1993, Trends in biochemical sciences.

[40]  W. Engel,et al.  Transfer of beta-amyloid precursor protein gene using adenovirus vector causes mitochondrial abnormalities in cultured normal human muscle. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[41]  M. Dalakas,et al.  Immune‐mediated conditions and antibodies associated with sporadic inclusion body myositis , 1998, Muscle & nerve.

[42]  A. Goldberg,et al.  Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. , 1996, The New England journal of medicine.

[43]  A. Hedström,et al.  Inclusion body myositis: peripheral nerve involvement Combined morphological and electrophysiological studies on peripheral nerves , 1990, Journal of the Neurological Sciences.

[44]  C. Oddis.  Therapy for myositis , 1991, Current opinion in rheumatology.

[45]  M. Mahowald,et al.  Inclusion body myositis and renal cell carcinoma. Report of two cases and review of the literature. , 1993, Arthritis and rheumatism.

[46]  A. Oldfors,et al.  Upregulation of Fas/Fas ligand in inclusion body myositis , 1998, Annals of neurology.

[47]  J. Shapiro,et al.  Inflammatory Myopathy Causing Pharyngeal Dysphagia: A New Entity , 1996, The Annals of otology, rhinology, and laryngology.

[48]  Thomas Wisniewski,et al.  Apolipoprotein E: A pathological chaperone protein in patients with cerebral and systemic amyloid , 1992, Neuroscience Letters.

[49]  J. Hardy,et al.  The presenilins and Alzheimer's disease. , 1997, Human molecular genetics.

[50]  W. Engel,et al.  Use of anti‐neurofilament antibody to identify paired‐helical filaments in inclusion‐body myositis , 1996, Annals of neurology.

[51]  R. Prayson,et al.  Ubiquitin immunostaining and inclusion body myositis: study of 30 patients with inclusion body myositis. , 1997, Human pathology.

[52]  W. Engel,et al.  Light and electron microscopic localization of beta-amyloid protein in muscle biopsies of patients with inclusion-body myositis. , 1992, The American journal of pathology.

[53]  Reinhard Hohlfeld,et al.  T-cell heterogeneity in muscle lesions of inclusion body myositis , 1998, Journal of Neuroimmunology.

[54]  B. Permanne,et al.  Presenilin-1 is associated with Alzheimer's disease amyloid. , 1997, The American journal of pathology.

[55]  J. Dambrosia,et al.  Treatment of inclusion-body myositis with IVIg , 1997, Neurology.

[56]  S. Dimauro,et al.  Inclusion body myositis and myopathies , 1995, Annals of neurology.

[57]  W. Engel,et al.  New advances in inclusion-body myositis. , 1993, Current opinion in rheumatology.

[58]  M. Pericak-Vance,et al.  Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[59]  W. Engel,et al.  Prion protein is strongly immunolocalized at the postsynaptic domain of human normal neuromuscular junctions , 1993, Neuroscience Letters.

[60]  Chou Sm,et al.  Inclusion body myositis: analysis of 32 cases. , 1992, The Journal of rheumatology.

[61]  V. Askanas,et al.  New developments in hereditary inclusion body myopathies , 1997, Annals of neurology.

[62]  D. Pollen,et al.  Familial and sporadic Alzheimer's disease , 1996, Neurology.

[63]  A. Roses,et al.  Apolipoprotein E alleles in sporadic inclusion‐body myositis and hereditary inclusion‐body myopathy , 1996, Annals of neurology.

[64]  J. Mendell,et al.  Microvascular deposition of complement membrane attack complex in dermatomyositis. , 1986, The New England journal of medicine.

[65]  F L Mastaglia,et al.  Apolipoprotein E ϵ4 in inclusion body myositis , 1995 .

[66]  A. Engel,et al.  Unexpected sarcolemmal complement membrane attack complex deposits on nonnecrotic muscle fibers in muscular dystrophies , 1998, Neurology.

[67]  A. Ciechanover,et al.  The ubiquitin system for protein degradation. , 1992, Annual review of biochemistry.

[68]  B. Hyman,et al.  Studies of Amyloid β‐Protein Precursor Expression in Alzheimer's Disease , 1991, Annals of the New York Academy of Sciences.

[69]  Paolo Confalonieri,et al.  Inflammatory myopathies and systemic disorders: a review of immunopathogenetic mechanisms and clinical features , 1997, Journal of Neurology.

[70]  Charles R. Harringtonaa,et al.  Apolipoprotein E type ϵ4 allele frequency is not increased in patients with sporadic inclusion-body myositis , 1995, Neuroscience Letters.

[71]  Y. Herishanu,et al.  Inclusion body myositis in post‐poliomyelitis muscular atrophy , 1988, Acta neurologica Scandinavica.

[72]  D. Dickson,et al.  Recognition of tau epitopes by anti-neurofilament antibodies that bind to Alzheimer neurofibrillary tangles. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[73]  V. Fried,et al.  Activation-induced ubiquitination of the T cell antigen receptor. , 1992, Science.

[74]  E. Holme,et al.  Mitochondrial DNA Deletions in Muscle Fibers in Inclusion Body Myositis , 1995, Journal of neuropathology and experimental neurology.

[75]  G. Perry,et al.  Advanced Maillard reaction end products are associated with Alzheimer disease pathology. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[76]  S. Dimauro,et al.  Multiple mitochondrial DNA deletions in sporadic inclusion body myositis: A study of 56 patients , 1996, Annals of neurology.

[77]  H. Wiśniewski,et al.  Molecular cloning and characterization of a cDNA encoding the cerebrovascular and the neuritic plaque amyloid peptides. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[78]  V. Askanas,et al.  Human muscle macrophages express &bgr;‐amyloid precursor and prion proteins and their mRNAs , 1995, Neuroreport.

[79]  D. Selkoe,et al.  Normal and abnormal biology of the beta-amyloid precursor protein. , 1994, Annual review of neuroscience.

[80]  A. Leclerc,et al.  Ubiquitin and β-amyloid-protein in inclusion body myositis (IBM), familial IBM-like disorder and oculopharyngeal muscular dystrophy: An immunocytochemical study , 1993, Neuromuscular Disorders.

[81]  F L Mastaglia,et al.  Inclusion body myositis. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[82]  J. Mendell,et al.  Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments. , 1991, Archives of neurology.

[83]  R. Mayer,et al.  Ubiquitin in Neurodegenerative Diseases , 1993, Brain pathology.

[84]  J Miller,et al.  Inclusion body myositis in HIV-1 and HTLV-1 infected patients. , 1996, Brain : a journal of neurology.

[85]  H. Potter,et al.  α 1-Antichymotrypsin is associated solely with amyloid deposits containing the β-protein. Amyloid and cell localization of α 1-antichymotrypsin , 1990, Neurobiology of Aging.

[86]  Kucharz Ej.  [Inclusion body myositis]. , 1998, Polskie Archiwum Medycyny Wewnetrznej.

[87]  K. Ohno,et al.  Congenital myasthenic syndromes caused by mutations in acetylcholine receptor genes , 1997, Neurology.

[88]  W. Engel,et al.  Immunocytochemical localization of ubiquitin at human neuromuscular junctions , 1992, Neuropathology and applied neurobiology.

[89]  Z. Meiner,et al.  Inclusion body myositis: atypical clinical presentations. , 1996, European neurology.

[90]  F. Mastaglia,et al.  Treatment of inflammatory myopathies , 1997, Muscle & nerve.

[91]  W. Engel,et al.  beta-Amyloid precursor protein mRNA is increased in inclusion-body myositis muscle. , 1993, Neuroreport.

[92]  W. Engel,et al.  Nitric oxide-induced oxidative stress in autosomal recessive and dominant inclusion-body myopathies. , 1998, Brain : a journal of neurology.

[93]  W. Engel,et al.  Idiopathic inflammatory myopathies: inclusion‐body myositis, polymyositis, and dermatomyositis , 1994, Current opinion in neurology.

[94]  John Hardy,et al.  Amyloid, the presenilins and Alzheimer's disease , 1997, Trends in Neurosciences.

[95]  N. Cairns,et al.  Tau proteins of alzheimer paired helical filaments: Abnormal phosphorylation of all six brain isoforms , 1992, Neuron.

[96]  W. Engel,et al.  SCANNING FOR SOFT-TISSUE AMYLOID , 1977, The Lancet.

[97]  W. Engel,et al.  Immunolocalization of ubiquitin in muscle biopsies of patients with inclusion body myositis and oculopharyngeal muscular dystrophy , 1991, Neuroscience Letters.

[98]  K J Felice,et al.  Inclusion body myositis associated with a severe unilateral levodopa‐responsive upper extremity tremor , 1996, Muscle & nerve.

[99]  D. Selkoe,et al.  Twisted tubulofilaments of inclusion body myositis muscle resemble paired helical filaments of Alzheimer brain and contain hyperphosphorylated tau. , 1994, The American journal of pathology.

[100]  D. Selkoe,et al.  Immunochemical identification of the serine protease inhibitor α 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease , 1988, Cell.

[101]  H. Hartung,et al.  MHC Class l‐Mediated Cytotoxicity Does Not Induce Apoptosis in Muscle Fibers nor in Inflammatory T Cells: Studies in Patients with Polymyositis, Dermatomyositis, and Inclusion Body Myositis , 1996, Journal of neuropathology and experimental neurology.

[102]  D. Selkoe,et al.  Isolation of Low‐Molecular‐Weight Proteins from Amyloid Plaque Fibers in Alzheimer's Disease , 1986, Journal of neurochemistry.

[103]  J. Trojanowski,et al.  Phosphorylation of Neuronal Cytoskeletal Proteins in Alzheimer's Disease and Lewy Body Dementias a , 1994, Annals of the New York Academy of Sciences.

[104]  G. Glenner,et al.  Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein , 1984 .

[105]  R. Hohlfeld,et al.  T cell receptor repertoire in polymyositis: clonal expansion of autoaggressive CD8+ T cells , 1995, The Journal of experimental medicine.

[106]  M. Dalakas,et al.  Inclusion Body Myositis , 1997, Neurology.

[107]  G. Gibson,et al.  Inclusion body myositis (IBM) , 1983, Neurology.

[108]  C. Masters,et al.  Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[109]  B. Hyman.  Alzheimer's disease or Alzheimer's diseases? clues from molecular epidemiology , 1996, Annals of neurology.

[110]  D. Butterfield.  beta-Amyloid-associated free radical oxidative stress and neurotoxicity: implications for Alzheimer's disease. , 1997, Chemical research in toxicology.

[111]  J. Morrison,et al.  Progressive transformation of the cytoskeleton associated with normal aging and Alzheimer's disease , 1992, Brain Research.

[112]  W. Engel,et al.  Impaired innervation of cultured human muscle overexpressing βAPP experimentally and genetically: relevance to inclusion‐body myopathies , 1998, Neuroreport.